New products to lead Nicholas topline growth - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

New products to lead Nicholas topline growth

Apr 25, 2000

Nicholas Piramal has reported an above average topline growth of 13% (vis–a–vis the overall domestic pharmaceutical growth of 9%) primarily due to introduction of new products which contributed around Rs 500 m to the topline. These products were in the relatively faster growing cardiovascular segment. The other positives for the company during the year were the sale of its bulk drug business, the price revision allowed for Vitamin A (which would yield Rs 40 m next year) and the restructuring of its facility at Deonar which yielded cost benefits.

(Rs m) FY1999 FY2000 Change
Sales 4300.00 4865.00 13.1%
Other Income 188.00 182.00 -3.2%
Expenditure 3746.00 4200.00 12.1%
Operating Profit (EBDIT) 554.00 665.00 20.0%
Operating Profit Margin (%) 12.88% 13.67%  
Interest (net) 145.00 112.00 -22.8%
Depreciation 89.00 106.00 19.1%
Profit before Tax 508.00 629.00 23.8%
Other Adjustments      
Tax 55.00 60.00 9.1%
Profit after Tax/(Loss) 453.00 569.00 25.6%
Net profit margin (%) 10.53% 11.70%  


Equitymaster requests your view! Post a comment on "New products to lead Nicholas topline growth". Click here!

  

More Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY21); Net Profit Up 22.1% (Quarterly Result Update)

Aug 25, 2020 | Updated on Aug 25, 2020

For the quarter ended June 2020, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 22.1% YoY). Sales on the other hand came in at Rs 29 bn (down 16.2% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY20); Net Profit Up 11.7% (Quarterly Result Update)

Feb 5, 2020 | Updated on Feb 5, 2020

For the quarter ended December 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 11.7% YoY). Sales on the other hand came in at Rs 38 bn (up 9.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

More Views on News

Most Popular

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

How Much Money Do You Need to Be a Professional Trader? (Fast Profits Daily)

Sep 17, 2020

In this video I'll answer a question I get asked often: How much capital do I really need to trade the markets for a living? Let's find out...

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Sep 25, 2020 03:36 PM

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES - TEVA PHARMA COMPARISON

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS